



PHARMACEUTICAL 2017












PHARMACEUTICAL 2017





The relative strengths and weaknesses of Aclaris Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aclaris Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Aclaris Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 266%, being 264% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	138,556
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,223
Liabilities, Non-Current	372
Other Assets	37,048
Other Compr. Net Income	-120
Other Expenses	0
Other Liabilities	0
Other Net Income	488
Other Revenues	0
Property and Equipment	481
Research and Development	33,476
Selling, General and Administrative Expense	15,091

Output Variable	Value in 1000 USD
Assets	176,085
Liabilities	6,595
Expenses	48,567
Revenues	0
Stockholders Equity	169,490
Net Income	-48,079
Comprehensive Net Income	-48,139
Economic Capital Ratio	266%

